### DLGAP1-AS3 Gene Overview

**Gene Symbol:** DLGAP1-AS3  
**Location:** The DLGAP1-AS3 gene is a long non-coding RNA located on the human chromosome.

**General Description:** DLGAP1-AS3 (DLGAP1 Antisense RNA 3) is an antisense non-coding RNA associated with the DLGAP1 gene, which is implicated in synaptic signaling processes and is thought to play a role in neurodevelopment. The expression of non-coding RNA genes like DLGAP1-AS3 may have regulatory effects on their sense counterparts and could impact various cellular processes.

### Other Associated Genes
While the summaries you provided may detail the DLGAP1 gene, there may be associations with several other genes involved in similar pathways or processes:

1. **DLGAP1 (Discs large-associated protein 1)** - the core sense gene to which DLGAP1-AS3 is antisense.
2. **GRIN2B (Glutamate receptor ionotropic, NMDA 2B)** - Related to synaptic signaling and could be co-expressed in the same pathways.
3. **SYN1 (Synapsin I)** - Another gene that interacts with synaptic vesicles and could be connected to DLGAP1-AS3 regulation.
4. **MAPK (Mitogen-activated protein kinase) genes** - Pathways involving MAPK signaling may interact indirectly through the synaptic processes.

### Aging and Age-Related Diseases
Current research into non-coding RNAs suggests that alterations in their expression may be linked to various age-related conditions, particularly neurodegenerative diseases. Compelling evidence places DLGAP1 and its associated antisense RNA in the context of:

- **Neurodegenerative Disorders**: Dysregulation of synaptic function mediated by DLGAP1 has been implicated in diseases such as Alzheimer’s.
- **Cognitive Decline**: Changes in the expression of DLGAP1-AS3 might be relevant in the context of cognitive aging and could play a role in synaptic plasticity associated with memory and learning.

### Known Drug Interactions
As of now, the knowledge about specific drugs or drug classes interacting directly with DLGAP1-AS3 is limited, as most drug targets are proteins. However, since DLGAP1 is associated with synaptic function and neurodevelopment, drugs that modify glutamate receptor activity or neuroprotective agents may indirectly influence the expression or function of DLGAP1-AS3:

1. **Neuromodulators** (such as those affecting dopaminergic or glutamatergic systems)
2. **Antipsychotics or antidepressants** - being studied for their effects on synaptic pathways.

### Pathways and Biological Processes
DLGAP1-AS3 is likely involved in multiple biological processes, reflecting its role as an antisense RNA:

1. **Synaptic Vesicle Cycling**: DLGAP1 and its associated complex are critical in synapse formation and function.
2. **Cell Signaling Pathways**: Involvement in pathways associated with glutamate receptor signaling, which is fundamental for synaptic plasticity.
3. **Neurodevelopmental Processes**: Helps regulate gene expression crucial for neural development and maintenance.

### Conclusion
While research is ongoing, the DLGAP1-AS3 gene's potential roles in neurological function, aging, and disease warrant further investigation to elucidate its mechanisms and relevance in clinical contexts. Understanding how such non-coding RNAs interact with gene regulation and signaling pathways will enhance our insight into complex conditions like Alzheimer’s disease and other age-related cognitive declines.